Moderna Inc. (NASDAQ:MRNA) on Tuesday signed a long-term strategic agreement with the Mexican government to enhance local mRNA manufacturing capabilities.
Moderna’s Strategic Agreement Boosts Mexico’s mRNA Capabilities
The agreement includes a Memorandum of Understanding that supports “Plan Mexico,” aimed at building a local mRNA ecosystem and enabling access to Moderna’s respiratory vaccine portfolio.
Moderna and the Mexican Government will also collaborate on local clinical research and development programs based on Mexico’s health priorities and work to strengthen its pandemic preparedness framework.
Additionally, the deal will facilitate technology transfer to Laboratorios Liomont for domestic production of Moderna’s COVID-19 vaccine, with a commitment to supply up to 10 million doses for the 2025-2026 vaccination campaign.
The collaboration follows recent regulatory approvals for Moderna’s COVID-19 vaccine for individuals aged six months and older, which underscores the growing demand for these vaccines in Mexico. CEO Stéphane Bancel emphasized the importance of this partnership in bolstering pandemic preparedness and responding to public health needs.
Moderna’s Stock Shows Long-Term Strength Amid Market Fluctuations
The stock is currently trading 2.9% below its 20-day simple moving average (SMA) but is 37.7% above its 100-day SMA, demonstrating longer-term strength.
Shares have increased 31.63% over the past 12 months and are currently positioned closer to their 52-week highs than lows.
The RSI is at 53.64, which is considered neutral territory. Meanwhile, MACD is below its signal line, indicating bearish pressure on the stock.
The combination of neutral RSI and bearish MACD suggests mixed momentum.
- Key Resistance: $43.50
- Key Support: $41.00
Moderna’s Upcoming Earnings: Analysts’ Expectations
Moderna is set to report earnings on February 13, 2026.
- EPS Estimate: $-2.60 (Up from $-2.91 YoY)
- Revenue Estimate: $638.92 million (Down from $966.00 million YoY)
Analyst Consensus & Recent Actions:
The stock carries a Hold Rating with an average price target of $50.52. Recent analyst moves include:
- UBS: Neutral (Lowers Target to $34.00)
- Morgan Stanley: Equal-Weight (Lowers Target to $28.00)
- Jefferies: Initiated with Hold (Target $30.00)
Moderna’s Strong Momentum Reflected in Benzinga Edge Score
Below is the Benzinga Edge scorecard for Moderna, highlighting its strengths and weaknesses compared to the broader market:
- Momentum: Strong (Score: 88.42) — Stock is outperforming the broader market.
The Verdict: Moderna’s Benzinga Edge signal reveals a strong momentum setup. While the stock is positioned well in the market, traders should remain vigilant as the upcoming earnings report approaches.
MRNA Price Action: Moderna shares were up 0.76% at $42.27 during premarket trading on Tuesday, according to Benzinga Pro data.
Photo by pcruciatti via Shutterstock
